Description

Myxoma virus (MYXV), a Leporipoxvirus, is being developed as an oncolytic virotherapeutic for the treatment of a variety of human cancers. MYXV tropism for human cancer cells is largely mediated

Myxoma virus (MYXV), a Leporipoxvirus, is being developed as an oncolytic virotherapeutic for the treatment of a variety of human cancers. MYXV tropism for human cancer cells is largely mediated by intracellular signaling networks that regulate viral replication or innate antiviral response pathways. Thus, MYXV is fully or partially permissive for the majority of human cancer cells that harbor defects in antiviral signaling, but a minority are nonpermissive because the virus infection aborts before its completion.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2017-11-16
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.1038/s41598-017-15941-1
    • Identifier Type
      International standard serial number
      Identifier Value
      2045-2322
    Note

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Rahman, M. M., Bagdassarian, E., Ali, M. A., & Mcfadden, G. (2017). Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells. Scientific Reports, 7(1). doi:10.1038/s41598-017-15941-1

    Machine-readable links